Home >> Gastrointestinal >> Gastrointestinal >> Baked Goods >> Technology & Media >>

Eosinophilic Esophagitis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 67 | Code: MRS - 18260

Eosinophilic Esophagitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Eosinophilic Esophagitis - Pipeline Review, H1 2015’, provides an overview of the Eosinophilic Esophagitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis - Overview 8
Pipeline Products for Eosinophilic Esophagitis - Comparative Analysis 9
Eosinophilic Esophagitis - Therapeutics under Development by Companies 10
Eosinophilic Esophagitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Eosinophilic Esophagitis - Products under Development by Companies 14
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 15
Actavis plc 15
DBV Technologies S.A. 16
Dr. Falk Pharma GmbH 17
Lipella Pharmaceuticals, Inc. 18
Novartis AG 19
Oxagen Limited 20
Receptos, Inc. 21
Regeneron Pharmaceuticals, Inc. 22
Shire Plc 23
Teva Pharmaceutical Industries Limited 24
Eosinophilic Esophagitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Allergen for Milk Allergy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
budesonide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
budesonide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dupilumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EUR-1100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
OC-459 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
QAX-576 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
reslizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RPC-4046 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tacrolimus liposomal - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Eosinophilic Esophagitis - Recent Pipeline Updates 50
Eosinophilic Esophagitis - Dormant Projects 58
Eosinophilic Esophagitis - Product Development Milestones 59
Featured News & Press Releases 59
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 59
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 59
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 60
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 61
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 62
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 62
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 63
Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8
Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Eosinophilic Esophagitis - Pipeline by Actavis plc, H1 2015 15
Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H1 2015 16
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 17
Eosinophilic Esophagitis - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 18
Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2015 19
Eosinophilic Esophagitis - Pipeline by Oxagen Limited, H1 2015 20
Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H1 2015 21
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 22
Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2015 23
Eosinophilic Esophagitis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2015 50
Eosinophilic Esophagitis - Dormant Projects, H1 2015 58

List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8
Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing